AstraZeneca Keeps Pruning Drugs in $1.5 Billion Sale to Sobi
AstraZeneca Paludrine 100mg tablets, produced by AstraZeneca Plc, sit on a blister pack in this arranged photograph taken in London, U.K. (Photographer: Simon Dawson/Bloomberg)

AstraZeneca Keeps Pruning Drugs in $1.5 Billion Sale to Sobi

(Bloomberg) -- AstraZeneca Plc agreed to sell U.S. rights to the respiratory medicine Synagis to Sweden’s Sobi for at least $1.5 billion, another move in the U.K. drugmaker’s efforts to purge its p...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.